Journal Pre-proof

Troponin Release after Pulmonary Vein Isolation using Pulsed Field Ablation compared to Radiofrequency and Cryoballoon Ablation

Philipp Krisai, MD, Sven Knecht, PhD, Patrick Badertscher, MD, Aline Mühl, MSc, Stefan Osswald, MD, Laurent Roten, MD, Tobias Reichlin, MD, Christian Sticherling, MD, Michael Kühne, MD

PII: S1547-5271(22)02034-3
DOI: https://doi.org/10.1016/j.hrthm.2022.05.020
Reference: HRTHM 9416

To appear in: Heart Rhythm

Received Date: 12 May 2022
Revised Date: 16 May 2022
Accepted Date: 17 May 2022


This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier Inc. on behalf of Heart Rhythm Society.
Troponin Release after Pulmonary Vein Isolation using Pulsed Field Ablation compared to Radiofrequency and Cryoballoon Ablation

Philipp Krisai\textsuperscript{1,2} MD, Sven Knecht\textsuperscript{1,2} PhD, Patrick Badertscher\textsuperscript{1,2} MD, Aline Mühl MSc\textsuperscript{3}, Stefan Osswald\textsuperscript{1,2} MD, Laurent Roten\textsuperscript{3} MD, Tobias Reichlin\textsuperscript{3} MD, Christian Sticherling\textsuperscript{1,2} MD, Michael Kühne\textsuperscript{1,2} MD

\textsuperscript{1} Cardiology Division, Department of Medicine, University Hospital Basel, University Basel, Basel, Switzerland
\textsuperscript{2} Cardiovascular Research Institute Basel, University Hospital Basel, University Basel, Basel, Switzerland
\textsuperscript{3} Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Running title: Troponin release after PVI

Word count: 705

Address for correspondence:
Prof. Dr. med Michael Kühne
Cardiology/Electrophysiology
University Hospital Basel
Petersgraben 4, 4031 Basel
Switzerland
Keywords: atrial fibrillation; pulsed field ablation; troponin T; radiofrequency ablation; cryo ablation.
Pulmonary vein isolation (PVI) is the cornerstone of interventional atrial fibrillation (AF) treatment. Current ablation modalities include radiofrequency ablation (RF), cryo-ablation and the recently available pulsed field ablation (PFA). Little is known on differences in post-procedural cardiac biomarkers as a marker of cardiac injury. We therefore investigated releases in high-sensitivity Troponin-T (hsTnT) after each modality.

We prospectively enrolled 60 patients undergoing their first PVI (20 per ablation modality) at two Swiss centers and measured hsTnT one day before and the morning after the procedure (Elecsys 2010 high-sensitivity troponin T, Roche Diagnostics). For RF we used irrigated-tip Thermocool© catheters at 25-50W (Biosense Webster), for Cryo-ablation 28mm Arctic Front Advance Pro© balloon catheters (Medtronic) and for PFA Farawave© catheters (Boston Scientific). Besides PVI, no additional lesion sets were performed. The study was approved by the local ethics committees and adhered to the Helsinki Declaration. Mean and median values were compared with ANOVA and Kruskal-Wallis tests, respectively, and between group comparisons with post-hoc analyses using SAS® Studio and SPSSv28.0.1.0.

Overall, mean (standard deviation [SD]) age was 66.4 (10.9) years, 19 (31.7%) patients were female and 34 (56.7%) patients had paroxysmal AF. Mean (SD) CHADS-VASc score was 2.3 (1.3), left atrial diameter 40.7 (6.9) mm and left ventricular ejection fraction 56.3 (11.1)%. Comparing RF, Cryo and PFA, we found no significant differences in age (63.9, 64.7 and 70.6 years; p=0.10), LA diameter (42.8, 39.3 and 38.9 mm; p=0.23) or paroxysmal AF (11, 12 and 11 patients; p=0.93), but PFA patients had a higher CHA2DS2-VASc score (2.1, 1.9 and 3.0; p=0.03).

Respective ablation times for RF and Cryo were 1328 (316) and 1097 (325) seconds and 38.2 (13.3) applications for PFA (84 [29] seconds). Pre-interventional mean (SD)
hsTnT levels were slightly higher in the PFA group (15.2 [10.7]) compared to RF (8.9 [4.3]; p=0.02) and Cryo (8.0 [3.3] ng/l; p=0.005). Post-interventional mean (SD) hsTnT levels were considerably higher in the PFA group (1571.0 [691.4]) compared to RF (962.3 [376.5]; p<0.001) and Cryo (832.6 [251.1] ng/l; p<0.001). The mean (SD) change in hsTnT was significantly higher in the PFA group (1555.9 [689.7]) compared to the RF (953.4 [376.2]; p<0.001) and Cryo (824.7 [251.3] ng/l; p<0.001) groups, while we did not identify a difference between the latter two groups (p=0.67) (Figure). Median (interquartile range) changes in hsTnT were similarly higher in the PFA group (1377.0 [1047.0-1939.5]) compared to the RF (911.5 [747.0-1128.5]; p=0.003) and Cryo (762.5 [653.0-964.0] ng/l; p=0.002) groups with no difference between the latter two (p=0.49).

We found hsTnT releases after PFA to be approximately 1.6 and 1.9 times higher compared to RF and Cryo-ablation, respectively. Intuitively, this higher increase in cardiac biomarkers may be a surrogate for larger, more antral lesions created by the flower shape of the Farawave© catheter. However, a recent study showed similar extent and morphology of PVI by PFA and thermal energies.² Alternatively, the larger increase in biomarkers may indicate more comprehensive ablation inside the pulmonary vein antrum by the basket shape of the Farawave© catheter compared to linear, antral ablation by thermal energies. Prospective studies need to investigate if the more pronounced increase in cardiac biomarkers after PFA translates into enhanced lesion durability over time or impacts safety compared to other modalities. Limitations of our study include the cross-sectional non-randomized design, the limited sample size and the lack of clinical outcomes to investigate the clinical significance of different hsTnT releases.
In conclusion, we found a significantly higher increase of hs-cTnT as a surrogate for myocardial injury after PFA compared to RF and cryo-ablation.
Disclosures

MK reports personal fees from Bayer, personal fees from Böhringer Ingelheim, personal fees from Pfizer BMS, personal fees from Daiichi Sankyo, personal fees from Medtronic, personal fees from Biotronik, personal fees from Boston Scientific, personal fees from Johnson&Johnson, personal fees from Roche, grants from Bayer, grants from Pfizer, grants from Boston Scientific, grants from BMS, grants from Biotronik, grants from Daiichi Sankyo; PK received grants from the University of Basel, the Mach-Gaensslen foundation and the Bangerter-Rhyner foundation; SK reports grant from the Stiftung Kardiovaskuläre Forschung, outside the submitted work; CS has received speaker honoraria from Biosense Webster, Boston Scientific and Medtronic and research grants from Biosense Webster, Daiichi-Sankyo, and Medtronic; He is a proctor for Medtronic (Cryoballoon). PB received grants from the University of Basel, Stiftung für Herzschrittmacher und Elektrophysiologie, Johnson&Johnson and personnel fees from Abbott. TR received research grants from the Swiss National Science Foundation, the Swiss Heart Foundation and the sitem insel support fund. Speaker/consulting honoraria from Abbott/SJM, Bayer, Biosense-Webster, Biotronik, Boston-Scientific, Daiichi Sankyo, Farapulse, Medtronic and Pfizer-BMS paid to his institution without effect on his personal remuneration. Support for his institution’s fellowship program from Abbott/SJM, Biosense-Webster, Biotronik, Boston-Scientific and Medtronic. LR received speaker/consulting honoraria from Medtronic and Abbott.

Data Availability

All data will be shared upon reasonable request to the corresponding author.
References


Figure legends

Figure Change in high-sensitivity Troponin T stratified by ablation modality. Boxes contain interquartile range, horizontal lines the median, crosses and numbers the mean, whiskers the most extreme values within 1.5* interquartile range and further values as individual points.
Change in high sensitivity Troponin T

- p < 0.001
- p < 0.001
- p = 0.67

953 ng/l
825 ng/l
1556 ng/l